Q-omics provides the consensus-scored BCL9P1 profile across patient tissues and cancer cell-line models. BCL9P1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BCL9P1 is differentially expressed in 7, with the highest sampling consensus in LUAD. Additionally, BCL9P1 RNA expression shows 6,804 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUAD, and STAD as cancer lineages where BCL9P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL9P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL9P1 survival associations across molecular data types. BCL9P1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL9P1 RNA expression–survival associations across cancer types. High BCL9P1 expression shows unfavorable associations in KICH, UVM, ACC, KIRC and THCA, but favorable associations in MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BCL9P1 RNA expression.
This table summarizes BCL9P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BCL9P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL9P1 shows lower tumor expression in LUAD, LUSC and PRAD and higher tumor expression in HNSC, KIRC and LIHC. The LUAD box plot shows higher BCL9P1 RNA expression in normal versus tumor tissue (log2 FC = −0.159, t-test p < 0.001).
This table shows molecular features associated with BCL9P1 in patient tissues and cancer cell lines. In patient samples, BCL9P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
